Use of atomoxetine as the drug of choice in adults with ADHD in clinical practice Case report

Article Sidebar

Requires Subscription PDF (Język Polski)


Published: Mar 31, 2025
DOI: https://doi.org/10.24292/01.MF.0125.20
Keywords:
atomoxetine, ADHD, anxiety disorders, depression, alcohol use disorder

Main Article Content

Tomasz M. Gondek
1. Instytut Studiów Społecznych, Uniwersytet Dolnośląski DSW, Wrocław. 2. Gabinety Psychologiczne Iter, Wrocław

Abstract

This article discusses key aspects of initiating and monitoring ADHD treatment in specific groups of patients in whom, due to characteristic features in the medical history, non-stimulant treatment, primarily atomoxetine, may be the preferred choice. The pharmacology of atomoxetine, its mechanism of action, pharmacokinetics, dosage, and most common adverse effects are presented. Its usefulness in patients with ADHD comorbid with anxiety disorders, depression, history of alcohol dependence, risk of psychostimulant abuse, tics, and hoarding disorder is emphasized. Three case studies (patients with a history of alcohol dependence, anxiety after psychostimulants, and abuse of prescription psychostimulants) illustrate the practical application of atomoxetine in these specific clinical situations. In summary, atomoxetine is a valuable pharmacological option for the treatment of ADHD in adults, especially where psychostimulants are contraindicated or their use is associated with increased risk.

Article Details

How to Cite
Gondek, T. M. (2025). Use of atomoxetine as the drug of choice in adults with ADHD in clinical practice. Medycyna Faktow (J EBM), 18(1(66), 134-139. https://doi.org/10.24292/01.MF.0125.20
Issue
Vol 18 No 1(66) (2025)
Section
Articles

Copyright © by Medical Education. All rights reserved.

References

1. Salari N, Ghasemi H, Abdoli N et al. The global prevalence of ADHD in children and adolescents: a systematic review and meta-analysis. Ital J Pediatr. 2023; 49: 48.
2. Kessler RC, Adler L, Barkley R et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry. 2006; 163: 716-23.
3. Gondek TM, Todzia-Kornaś A, Szczegielniak A. Stanowisko grupy badawczej Female ADHD Research Group i Sekcji Kształcenia Specjalizacyjnego PTP dotyczące kontrowersyjnych doniesień medialnych na temat ADHD u osób dorosłych. Psychiatria Spersonalizowana. 2023; 2: 125-7.
4. Murawiec S, Szulc A, Gondek T et al. Sprawozdanie z dyskusji: „ADHD i ASD – debata, jak się odnaleźć pomiędzy wytycznymi a presją nowych czasów”. XVIII Międzynarodowy Kongres Psychiatria Medforum 2024. Psychiatria Spersonalizowana. 2025; 4(1): 15-24.
5. Gondek T, Stramecki F, Cieśla M et al. Diagnostyka i postępowanie terapeutyczne u dorosłych z ADHD. Rekomendacje Sekcji Kształcenia Specjalizacyjnego Polskiego Towarzystwa Psychiatrycznego i koalicji organizacji na rzecz osób z ADHD – 2024 r. Psychiatria Spersonalizowana/ Personalized Psychiatry. 2024; 3(3): 43-73.
6. Crunelle CL, van den Brink W, Moggi F et al. International consensus statement on screening, diagnosis and treatment of substance use disorder patients with comorbid attention deficit/hyperactivity disorder. Eur Addict Res. 2018; 24: 43-51.
7. Quinn PD, Chang Z, Hur K et al. ADHD medication and substance-related problems. Am J Psychiatry. 2017; 174: 877-85.
8. Jaffe RJ, Coffey BJ. Pharmacologic treatment of comorbid attention-deficit/hyperactivity disorder and Tourette and tic disorders. Child Adolesc Psychiatr Clin N Am. 2022; 31: 469-77.
9. Kratochvil CJ, Newcorn JH, Arnold LE et al. Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms. J Am Acad Child Adolesc Psychiatry. 2005; 44: 915-24.
10. Grassi G, Micheli L, Di Cesare Mannelli L et al. Atomoxetine for hoarding disorder: a pre-clinical and clinical investigation. J Psychiatr Res. 2016; 83: 240-8.